查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1401893

2030年視網膜疾病治療的全球市場預測：按類型、疾病類型、治療方法、劑型、給藥途徑、配銷通路、最終用戶和地區進行分析

Retinal Disease Therapeutics Market Forecasts to 2030 - Global Analysis By Type, Disorder Type (Genetic and Age Related), Treatment Technique, Dosage Form, Route of Administration, Distribution Channel, End User and by Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2023 年全球視網膜疾病治療市場規模為 139.9 億美元，預計到 2030 年將達到 296 億美元，預測期內複合年成長率為 11.3%。

一組稱為視網膜疾病的疾病會影響視網膜（眼睛後部的感光組織）。這些疾病會損害視網膜的正常功能，並可能導致失明或視力障礙。此外，視網膜疾病治療的目標是控制和治療這些病症，以維持或改善患者的視力。根據特定的疾病及其嚴重程度，可以使用多種治療方法，包括藥物、雷射療法、手術和植入裝置。

根據世界衛生組織（WHO）發布的《世界視力報告》，全球約有22億人患有視力障礙，其中約6,000萬人失明。

糖尿病盛行率增加

由於飲食和生活方式的改變導致全世界糖尿病患者數量不斷增加，視網膜疾病治療正在經歷顯著成長。此外，全球糖尿病患者數量的增加與解決糖尿病視網膜併發症的治療需求的增加直接相關。這是因為糖尿病是糖尿病視網膜病變的主要危險因素，而糖尿病視網膜病變常導致視力喪失。

缺乏治療依從性

某些視網膜疾病需要持續的、有時是侵入性的治療。患者因不適、恐懼或其他問題而抵制，可能會導致對此類治療計劃的不一致醫囑遵從性。此外，醫囑遵從性性差會降低治療性介入的有效性並危及患者的長期結果。提高治療便利性和解決患者擔憂對於提高醫囑遵從性至關重要。

個體化醫療的發展

透過將基因組和分子資料不斷整合到臨床實踐中，可以實現視網膜疾病治療中的個人化醫療。全面的基因譜和生物標記分析可以開發針對每位患者獨特基因組成的標靶治療。此外，這種旨在最大限度地減少副作用和最佳化治療效果的策略可以為精準醫學帶來重大進步。

負擔能力和經濟障礙

經濟不平等和高昂的治療費用可能嚴重阻礙獲得視網膜疾病的治療方法。除了限制患者就醫之外，財務不安全也給衛生系統帶來壓力，並使其難以提供全面的照護。經濟衰退和其他景氣衰退可能會加劇這些障礙，並危及尖端視網膜治療的公平分配。

COVID-19 的影響：

視網膜疾病治療市場受到 COVID-19大流行的嚴重影響。由於醫療保健系統的中斷、疫情應對資源的重新分配以及患者獲得常規護理的機會有限，視網膜疾病的診斷和治療被推遲。暫停的臨床試驗阻礙了新治療方法的開發。此外，不斷變化的醫療保健優先事項和經濟不確定性可能會影響市場動態，並對視網膜疾病的研究經費和治療方法發展產生長期影響。此次疫情增加了遠端醫療解決方案在視網膜疾病治療中的使用，並凸顯了強大的醫療保健系統的重要性。

預計黃斑部病變部分在預測期內將是最大的部分

黃斑部病變領域在視網膜疾病治療市場中佔有最大佔有率。在老年人中，黃斑部病變，更具體地說是老齡化黃斑部病變（AMD），是常見的，也是視力喪失的主要原因。此外，全球人口高齡化正在推動該行業的崛起。視網膜的中央部分黃斑部受到 AMD 的影響，導致視力扭曲、模糊，在極端情況下甚至會喪失中央視力。抗 VEGF 藥物和其他減緩病情進展的標靶治療在商業上可用於治療黃斑部病變。

預測期內，居家醫療領域預估複合年成長率最高

在這個市場中，居家醫療領域正以最高的複合年成長率成長。對以患者為中心的護理的需求、人口高齡化以及允許在家中進行更複雜治療的技術進步都促進了居家醫療的普及。此外，居家醫療服務包括廣泛的醫療和非醫療治療，例如藥物管理、慢性病監測和復健治療，所有這些都可以在您舒適的家中進行。

佔有率最大的地區

預計北美將佔據全球視網膜疾病治療藥物市場的最大佔有率。該地區人口眾多，人口高齡化，更容易患視網膜疾病，醫療基礎設施先進，眼科治療研發生態系統蓬勃發展，這是該地區的主導因素。大型製藥公司、學術研究中心和最先進的醫療設施是北美始終保持視網膜疾病治療行業領導者地位的一些因素。該地區享有的另一個優勢是積極的法規環境，鼓勵創新並加速新治療方法的核准流程。

複合年成長率最高的地區：

在視網膜疾病治療藥物市場中，歐洲地區預期複合年成長率最高。該地區的優勢包括完善的醫療保健系統、與老齡化相關的視網膜疾病的高發病率以及較早獲得最先進治療的機會。英國、德國和法國等歐洲國家高度重視眼科研究和開發，推動視網膜疾病治療方法的改進。此外，該地區的顯著成長也歸功於有利的法律規範以及製藥公司和學術機構之間不斷成長的合作夥伴關係。

免費客製化服務：

訂閱此報告的客戶可以利用以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與企業的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計/預測/複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 研究資訊來源
    • 主要研究資訊來源
    • 二次研究資訊來源
    • 先決條件

第3章市場趨勢分析

  • 介紹
  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 最終用戶分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章全球視網膜疾病治療藥物市場：依類型

  • 介紹
  • 黃斑部病變
  • 糖尿病眼科疾病
  • 視網膜剝離
  • 視網膜母細胞瘤
  • 黃斑皺紋
  • 黃斑裂孔
  • 飛蚊症
  • 其他類型

第6章全球視網膜疾病治療藥物市場：依疾病類型

  • 介紹
  • 遺傳上
  • 老齡化

第7章全球視網膜疾病治療藥物市場：依治療方法分類

  • 介紹
  • 雷射
  • 冷凍的
  • 移植
  • 縮排
  • 氣壓式融合術
  • 鞏膜屈曲
  • 玻璃體切除術

第8章全球視網膜疾病治療藥物市場：按劑型

  • 介紹
  • 凝膠
  • 眼藥水
  • 膠囊和錠劑
  • 眼藥水
  • 軟膏
  • 其他劑型

第9章全球視網膜疾病治療藥物市場：依給藥途徑給藥

  • 介紹
  • 口服
  • 局部的
  • 玻璃體內

第10章全球視網膜疾病治療藥物市場：依配銷通路

  • 介紹
  • 醫院藥房
  • 線上藥房
  • 零售藥房
  • 直接競標
  • 其他配銷通路

第11章全球視網膜疾病治療藥物市場：依最終用戶分類

  • 介紹
  • 醫院
  • 門診手術中心
  • 居家醫療
  • 其他最終用戶

第12章全球視網膜疾病治療藥物市場：按地區

  • 介紹
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 中東和非洲其他地區

第13章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第14章 公司簡介

  • Santen Pharmaceutical Co. Ltd.
  • AbbVie Inc.
  • Johnson & Johnson Services, Inc
  • Bayer AG
  • Regeneron Pharmaceuticals, Inc.
  • Adverum Biotechnologies, Inc.
  • Roche Holding AG
  • Genentech, Inc.
  • Alcon Inc.
  • Novartis AG
  • F. Hoffmann-La Roche AG
  • Senju Pharmaceutical Co., Ltd.
  • Bausch Health Companies Inc.
  • Allergan plc
  • Sun Pharmaceutical Industries Ltd.
  • Merck & Co., Inc.
  • Spark Therapeutics, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Clearside Biomedical, Inc.
  • Kubota Pharmaceutical Holdings Co., Ltd.
Product Code: SMRC24413

According to Stratistics MRC, the Global Retinal Disease Therapeutics Market is accounted for $13.99 billion in 2023 and is expected to reach $29.60 billion by 2030 growing at a CAGR of 11.3% during the forecast period. A collection of disorders known as retinal diseases impact the retina, the light-sensitive tissue found at the rear of the eye. These illnesses have the potential to impair the retina's normal function, which could result in blindness or visual impairment. Moreover, the goal of therapies for retinal diseases is to control and treat these conditions in order to maintain or enhance a patient's vision. Depending on the exact ailment and its severity, different treatment modalities may be used, such as medication, laser therapy, surgery, and implantable devices.

According to the World Vision Report released by the World Health Organisation (WHO), nearly 2.2 billion people suffer from vision impairment worldwide, of which approximately 60 million people are blind.

Market Dynamics:

Driver:

Expanding diabetes incidence

Retinal disease therapies are seeing significant growth due to the rise in diabetes cases worldwide, which is being caused by dietary and lifestyle modifications. Moreover, the increasing number of diabetes cases globally is directly correlated with an increased demand for therapeutics addressing diabetic retinal complications, as diabetes is a major risk factor for diabetic retinopathy, a condition that frequently results in vision impairment.

Restraint:

Lack of compliance with treatment

Frequent intravitreal injections are one of the ongoing, occasionally invasive treatments required for certain retinal diseases. Inconsistent adherence to these treatment plans may result from patient resistance brought on by discomfort, fear, or other issues. Additionally, poor adherence reduces the efficacy of therapeutic interventions and may jeopardize patients' long-term results. Improving treatment convenience and addressing patient concerns are essential for raising adherence rates.

Opportunity:

Developments in customized medicine

Personalized medicine in retinal disease therapeutics is made possible by the continuous integration of genomic and molecular data into clinical practice. Targeted therapies can be developed according to each patient's unique genetic composition thanks to thorough genetic profiling and biomarker analysis. Furthermore, precision medicine may advance significantly with this strategy, which aims to minimize side effects and optimize treatment efficacy.

Threat:

Affordability and economic barriers

The availability of treatments for retinal diseases may be severely hampered by economic inequality and high treatment expenses. In addition to restricting patient access, financial worries can put pressure on healthcare systems and make it more difficult to provide complete care. Recessions and other economic downturns have the potential to worsen these obstacles and put the fair distribution of cutting-edge retinal treatments in jeopardy.

COVID-19 Impact:

The market for treatments for retinal diseases has been greatly impacted by the COVID-19 pandemic. Diagnosis and treatment of retinal diseases have been delayed due to disruptions in healthcare systems, redirection of resources to pandemic response, and restrictions on patient access to routine care. Interruptions in clinical trials have impeded the development of new treatments. Furthermore, changes in healthcare priorities and economic uncertainty have affected market dynamics, potentially having long-term effects on funding for research and the development of treatments for retinal diseases. The pandemic has increased the use of telemedicine solutions in the treatment of retinal diseases and highlighted the significance of robust healthcare systems.

The Macular Degeneration segment is expected to be the largest during the forecast period

In the market for treatments for retinal diseases, the macular degeneration segment holds the largest share. Among older adults, macular degeneration-more specifically, age-related macular degeneration, or AMD-is a common and primary cause of vision loss. Moreover, the aging population on a global scale is driving the prominence of this segment. The macula, the core portion of the retina, is impacted by AMD, which can cause vision distortion or blurriness and, in extreme situations, central vision loss. Anti-VEGF medications and other targeted treatments meant to impede the advancement of the condition are available on the market for macular degeneration therapeutics.

The Home Healthcare segment is expected to have the highest CAGR during the forecast period

In the market, the Home Healthcare segment is growing at the highest CAGR. The need for patient-centered care, the aging population, and technological advancements that enable more complex treatments to be administered at home have all contributed to the rise in popularity of home healthcare. Additionally, a vast array of medical and non-medical treatments is included in home healthcare services, such as medication administration, chronic condition monitoring, and rehabilitation therapy delivered to patients in the comfort of their own homes.

Region with largest share:

In the global retinal disease therapeutics market, North America is expected to hold the largest share. The region's large and aging population, which makes it vulnerable to retinal diseases, its sophisticated healthcare infrastructure, and a thriving ecosystem of ophthalmic treatment-focused research and development activities all, contribute to its leadership. Major pharmaceutical companies, academic research centers, and cutting-edge healthcare facilities are some of the factors that consistently make North America a leader in the retinal disease therapeutics industry. A proactive regulatory environment that encourages innovation and speeds up the approval process for new treatments is another advantage that the region enjoys.

Region with highest CAGR:

In the market for treatments for retinal diseases, the Europe region is anticipated to have the highest CAGR. Benefits to the area include an established healthcare system, a high rate of age-related retinal diseases, and the early adoption of cutting-edge therapies. The United Kingdom, Germany, and France are among the European nations that place a high priority on ophthalmology research and development, which promotes improvements in the treatments for retinal diseases. Moreover, the notable growth in the region is also attributed to favourable regulatory frameworks and growing partnerships between pharmaceutical companies and academic institutions.

Key players in the market:

Some of the key players in Retinal Disease Therapeutics market include Santen Pharmaceutical Co. Ltd., AbbVie Inc., Johnson & Johnson Services, Inc, Bayer AG, Regeneron Pharmaceuticals, Inc., Adverum Biotechnologies, Inc., Roche Holding AG, Genentech, Inc., Alcon Inc., Novartis AG, F. Hoffmann-La Roche AG, Senju Pharmaceutical Co., Ltd. , Bausch Health Companies Inc., Allergan plc, Sun Pharmaceutical Industries Ltd., Merck & Co., Inc., Spark Therapeutics, Inc., Teva Pharmaceutical Industries Ltd., Clearside Biomedical, Inc. and Kubota Pharmaceutical Holdings Co., Ltd.

Key Developments:

In October 2023, Bayer AG has entered into an antibody discovery, option, and license agreement with Twist Bioscience Corporation, a company offering high-quality synthetic DNA using its silicon platform. The company's "Library of Libraries," a collection of synthetic antibody libraries that harnesses innovative structural and developability features to cover a wide range of antibody drug targets, is tailored to address specific challenges in antibody discovery.

In July 2023, Santen Pharmaceutical Co., Ltd. (hereafter Santen) announced today that it has signed licensing agreements and an asset transfer agreement with two U.S. companies. Santen has come to an out-licensing agreement with Visiox Pharmaceuticals, Inc. (hereafter Visiox) on the rights to product manufacturing, commercialization, and sales of OMLONTI®, an eye drop for the reduction of elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.

In February 2023, AbbVie and Capsida Biotherapeutics Inc. announced an expanded strategic collaboration to develop genetic medicines for eye diseases with high unmet need. AbbVie's extensive capabilities will be paired with Capsida's novel adeno-associated virus (AAV) engineering platform and manufacturing capability to identify and advance three programs. The collaboration builds upon the neurodegenerative disease partnership announced in 2021.

Types Covered:

  • Macular Degeneration
  • Diabetic Eye Disease
  • Retinal Detachment
  • Retinoblastoma
  • Macular Pucker
  • Macular Hole
  • Floaters
  • Other Types

Disorder Types Covered:

  • Genetic
  • Age Related

Treatment Techniques Covered:

  • Laser
  • Freezing
  • Implanting
  • Indenting
  • Pneumatic Retinopexy
  • Scleral Buckling
  • Vitrectomy

Dosage Forms Covered:

  • Gels
  • Eye solutions
  • Capsules & Tablets
  • Eye Drops
  • Ointments
  • Other Dosage Forms

Route of Administrations Covered:

  • Oral
  • Topical
  • Intravitreal

Distribution Channels Covered:

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy
  • Direct Tender
  • Other Distribution Channels

End Users Covered:

  • Hospitals
  • Ambulatory Surgical Centers
  • Home Healthcare
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Retinal Disease Therapeutics Market, By Type

  • 5.1 Introduction
  • 5.2 Macular Degeneration
  • 5.3 Diabetic Eye Disease
  • 5.4 Retinal Detachment
  • 5.5 Retinoblastoma
  • 5.6 Macular Pucker
  • 5.7 Macular Hole
  • 5.8 Floaters
  • 5.9 Other Types

6 Global Retinal Disease Therapeutics Market, By Disorder Type

  • 6.1 Introduction
  • 6.2 Genetic
  • 6.3 Age Related

7 Global Retinal Disease Therapeutics Market, By Treatment Technique

  • 7.1 Introduction
  • 7.2 Laser
  • 7.3 Freezing
  • 7.4 Implanting
  • 7.5 Indenting
  • 7.6 Pneumatic Retinopexy
  • 7.7 Scleral Buckling
  • 7.8 Vitrectomy

8 Global Retinal Disease Therapeutics Market, By Dosage Form

  • 8.1 Introduction
  • 8.2 Gels
  • 8.3 Eye solutions
  • 8.4 Capsules & Tablets
  • 8.5 Eye Drops
  • 8.6 Ointments
  • 8.7 Other Dosage Forms

9 Global Retinal Disease Therapeutics Market, By Route of Administration

  • 9.1 Introduction
  • 9.2 Oral
  • 9.3 Topical
  • 9.4 Intravitreal

10 Global Retinal Disease Therapeutics Market, By Distribution Channel

  • 10.1 Introduction
  • 10.2 Hospital Pharmacy
  • 10.3 Online Pharmacy
  • 10.4 Retail Pharmacy
  • 10.5 Direct Tender
  • 10.6 Other Distribution Channels

11 Global Retinal Disease Therapeutics Market, By End User

  • 11.1 Introduction
  • 11.2 Hospitals
  • 11.3 Ambulatory Surgical Centers
  • 11.4 Home Healthcare
  • 11.5 Other End Users

12 Global Retinal Disease Therapeutics Market, By Geography

  • 12.1 Introduction
  • 12.2 North America
    • 12.2.1 US
    • 12.2.2 Canada
    • 12.2.3 Mexico
  • 12.3 Europe
    • 12.3.1 Germany
    • 12.3.2 UK
    • 12.3.3 Italy
    • 12.3.4 France
    • 12.3.5 Spain
    • 12.3.6 Rest of Europe
  • 12.4 Asia Pacific
    • 12.4.1 Japan
    • 12.4.2 China
    • 12.4.3 India
    • 12.4.4 Australia
    • 12.4.5 New Zealand
    • 12.4.6 South Korea
    • 12.4.7 Rest of Asia Pacific
  • 12.5 South America
    • 12.5.1 Argentina
    • 12.5.2 Brazil
    • 12.5.3 Chile
    • 12.5.4 Rest of South America
  • 12.6 Middle East & Africa
    • 12.6.1 Saudi Arabia
    • 12.6.2 UAE
    • 12.6.3 Qatar
    • 12.6.4 South Africa
    • 12.6.5 Rest of Middle East & Africa

13 Key Developments

  • 13.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 13.2 Acquisitions & Mergers
  • 13.3 New Product Launch
  • 13.4 Expansions
  • 13.5 Other Key Strategies

14 Company Profiling

  • 14.1 Santen Pharmaceutical Co. Ltd.
  • 14.2 AbbVie Inc.
  • 14.3 Johnson & Johnson Services, Inc
  • 14.4 Bayer AG
  • 14.5 Regeneron Pharmaceuticals, Inc.
  • 14.6 Adverum Biotechnologies, Inc.
  • 14.7 Roche Holding AG
  • 14.8 Genentech, Inc.
  • 14.9 Alcon Inc.
  • 14.10 Novartis AG
  • 14.11 F. Hoffmann-La Roche AG
  • 14.12 Senju Pharmaceutical Co., Ltd.
  • 14.13 Bausch Health Companies Inc.
  • 14.14 Allergan plc
  • 14.15 Sun Pharmaceutical Industries Ltd.
  • 14.16 Merck & Co., Inc.
  • 14.17 Spark Therapeutics, Inc.
  • 14.18 Teva Pharmaceutical Industries Ltd.
  • 14.19 Clearside Biomedical, Inc.
  • 14.20 Kubota Pharmaceutical Holdings Co., Ltd.

List of Tables

  • Table 1 Global Retinal Disease Therapeutics Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Retinal Disease Therapeutics Market Outlook, By Type (2021-2030) ($MN)
  • Table 3 Global Retinal Disease Therapeutics Market Outlook, By Macular Degeneration (2021-2030) ($MN)
  • Table 4 Global Retinal Disease Therapeutics Market Outlook, By Diabetic Eye Disease (2021-2030) ($MN)
  • Table 5 Global Retinal Disease Therapeutics Market Outlook, By Retinal Detachment (2021-2030) ($MN)
  • Table 6 Global Retinal Disease Therapeutics Market Outlook, By Retinoblastoma (2021-2030) ($MN)
  • Table 7 Global Retinal Disease Therapeutics Market Outlook, By Macular Pucker (2021-2030) ($MN)
  • Table 8 Global Retinal Disease Therapeutics Market Outlook, By Macular Hole (2021-2030) ($MN)
  • Table 9 Global Retinal Disease Therapeutics Market Outlook, By Floaters (2021-2030) ($MN)
  • Table 10 Global Retinal Disease Therapeutics Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 11 Global Retinal Disease Therapeutics Market Outlook, By Disorder Type (2021-2030) ($MN)
  • Table 12 Global Retinal Disease Therapeutics Market Outlook, By Genetic (2021-2030) ($MN)
  • Table 13 Global Retinal Disease Therapeutics Market Outlook, By Age Related (2021-2030) ($MN)
  • Table 14 Global Retinal Disease Therapeutics Market Outlook, By Treatment Technique (2021-2030) ($MN)
  • Table 15 Global Retinal Disease Therapeutics Market Outlook, By Laser (2021-2030) ($MN)
  • Table 16 Global Retinal Disease Therapeutics Market Outlook, By Freezing (2021-2030) ($MN)
  • Table 17 Global Retinal Disease Therapeutics Market Outlook, By Implanting (2021-2030) ($MN)
  • Table 18 Global Retinal Disease Therapeutics Market Outlook, By Indenting (2021-2030) ($MN)
  • Table 19 Global Retinal Disease Therapeutics Market Outlook, By Pneumatic Retinopexy (2021-2030) ($MN)
  • Table 20 Global Retinal Disease Therapeutics Market Outlook, By Scleral Buckling (2021-2030) ($MN)
  • Table 21 Global Retinal Disease Therapeutics Market Outlook, By Vitrectomy (2021-2030) ($MN)
  • Table 22 Global Retinal Disease Therapeutics Market Outlook, By Dosage Form (2021-2030) ($MN)
  • Table 23 Global Retinal Disease Therapeutics Market Outlook, By Gels (2021-2030) ($MN)
  • Table 24 Global Retinal Disease Therapeutics Market Outlook, By Eye solutions (2021-2030) ($MN)
  • Table 25 Global Retinal Disease Therapeutics Market Outlook, By Capsules & Tablets (2021-2030) ($MN)
  • Table 26 Global Retinal Disease Therapeutics Market Outlook, By Eye Drops (2021-2030) ($MN)
  • Table 27 Global Retinal Disease Therapeutics Market Outlook, By Ointments (2021-2030) ($MN)
  • Table 28 Global Retinal Disease Therapeutics Market Outlook, By Other Dosage Forms (2021-2030) ($MN)
  • Table 29 Global Retinal Disease Therapeutics Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 30 Global Retinal Disease Therapeutics Market Outlook, By Oral (2021-2030) ($MN)
  • Table 31 Global Retinal Disease Therapeutics Market Outlook, By Topical (2021-2030) ($MN)
  • Table 32 Global Retinal Disease Therapeutics Market Outlook, By Intravitreal (2021-2030) ($MN)
  • Table 33 Global Retinal Disease Therapeutics Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 34 Global Retinal Disease Therapeutics Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 35 Global Retinal Disease Therapeutics Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 36 Global Retinal Disease Therapeutics Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
  • Table 37 Global Retinal Disease Therapeutics Market Outlook, By Direct Tender (2021-2030) ($MN)
  • Table 38 Global Retinal Disease Therapeutics Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 39 Global Retinal Disease Therapeutics Market Outlook, By End User (2021-2030) ($MN)
  • Table 40 Global Retinal Disease Therapeutics Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 41 Global Retinal Disease Therapeutics Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
  • Table 42 Global Retinal Disease Therapeutics Market Outlook, By Home Healthcare (2021-2030) ($MN)
  • Table 43 Global Retinal Disease Therapeutics Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.